Special Issue: “New Trends in Diabetes, Hypertension, and Cardiovascular Diseases—2nd Edition”
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(2), С. 449 - 449
Опубликована: Янв. 7, 2025
Cardiovascular
diseases
(CVDs)
encompass
a
range
of
conditions
affecting
both
the
heart
(e.g.,
coronary
disease
and
failure
[1])
blood
vessels
cerebrovascular
[2]
peripheral
artery
[3])
[...].
Язык: Английский
Integrated Care in Atrial Fibrillation: A Multidisciplinary Approach to Improve Clinical Outcomes and Quality of Life
Healthcare,
Год журнала:
2025,
Номер
13(3), С. 325 - 325
Опубликована: Фев. 5, 2025
Background:
Atrial
fibrillation
(AF)
is
the
most
common
arrhythmia
globally,
associated
with
serious
complications
such
as
stroke
and
heart
failure,
well
significant
impacts
on
patients’
quality
of
life.
Objectives:
This
theoretical
article
explores
role
integrated
care
in
management
AF,
highlighting
need
for
a
multidisciplinary
approach
that
goes
beyond
rhythm
rate
control.
Methods:
Through
review
literature,
this
prevalence
challenges
diagnosis,
socioeconomic
psychological
impact,
benefits
integrating
medical,
psychological,
social
interventions,
drawing
insights
from
studies
about
integrative
AF.
Results:
The
findings
highlight
managing
including
its
high
prevalence,
complex
patients.
Integrated
models,
combining
improve
treatment
adherence,
reduce
like
enhance
patient
Conclusions:
models
hold
promise
improving
outcomes
AF
patients
through
structured,
approaches.
Evidence
supports
reductions
cardiovascular
events,
hospitalizations,
mortality
when
adhering
to
clinical
guidelines,
emphasizing
education,
implementing
individualized
strategies.
Despite
challenges,
regional
disparities
suboptimal
implementation,
integration
teams
emerging
technologies
offers
way
delivery
accessibility.
Future
efforts
should
focus
personalizing
care,
promoting
professional
collaboration,
taking
advantage
technological
advances
optimize
promote
sustainable
health
systems.
Язык: Английский
Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling
Опубликована: Июнь 20, 2024
Non-Vitamin
K
Oral
Anticoagulants
(NOACs)
have
revolutionized
anticoagulant
therapy,
offering
improved
safety
and
efficacy
over
traditional
agents
like
warfarin.
This
review
comprehensively
examines
the
dual
roles
of
NOACs—Apixaban,
Rivaroxaban,
Edoxaban,
Dabigatran—not
only
as
anticoagulants
but
also
modulators
inflammation
via
Protease-Activated
Receptor
(PAR)
signaling.
We
highlight
unique
pharmacotherapeutic
properties
each
NOAC,
supported
by
key
clinical
trials
demonstrating
their
effectiveness
in
preventing
thromboembolic
events.
Beyond
established
roles,
emerging
research
suggests
that
NOACs
influence
through
PAR
signaling
pathways,
implicating
factors
such
FXa
Thrombin
modulation
inflammatory
responses.
synthesizes
current
evidence
on
anti-inflammatory
potential
NOACs,
exploring
impact
markers
conditions
atherosclerosis
diabetes.
By
delineating
mechanisms
which
mediate
effects,
this
work
aims
to
expand
therapeutic
utility,
new
perspectives
for
managing
diseases.
Our
findings
underscore
broader
implications
advocating
consideration
strategies
aimed
at
addressing
inflammation-related
pathologies.
comprehensive
synthesis
not
enhances
understanding
NOACs'
multifaceted
paves
way
future
applications
cardiovascular
health
Язык: Английский
Selective Modulation of PAR-2-Driven Inflammatory Pathways by Oleocanthal: Attenuation of TNF-α and Calcium Dysregulation in Colorectal Cancer Models
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(7), С. 2934 - 2934
Опубликована: Март 24, 2025
Colorectal
cancer
(CRC)
remains
a
principal
contributor
to
oncological
mortality
worldwide,
with
chronic
inflammation
serving
as
fundamental
driver
of
its
pathogenesis.
Protease-activated
receptor-2
(PAR-2),
G-protein-coupled
receptor,
orchestrates
inflammation-driven
tumorigenesis
by
potentiating
NF-κB
and
Wnt/β-catenin
signaling,
thereby
fostering
epithelial-mesenchymal
transition
(EMT),
immune
evasion,
therapeutic
resistance.
Despite
pathological
significance,
targeted
modulation
PAR-2
an
underexplored
avenue
in
CRC
therapeutics.
Oleocanthal
(OC),
phenolic
constituent
extra
virgin
olive
oil,
is
recognized
for
potent
anti-inflammatory
anti-cancer
properties;
however,
regulatory
influence
on
signaling
yet
be
elucidated.
This
study
interrogates
the
impact
OC
PAR-2-mediated
inflammatory
cascades
using
HT-29
Caco-2
cell
lines
subjected
lipopolysaccharide
(LPS)-induced
activation
PAR-2.
Expression
levels
TNF-α
were
quantified
through
Western
blotting
RT-PCR,
while
ELISA
assessed
secretion.
Intracellular
calcium
flux,
pivotal
modulator
PAR-2-driven
oncogenic
inflammation,
was
evaluated
via
Fluo-4
assays.
LPS
markedly
elevated
expression
at
both
mRNA
protein
cells
(p
<
0.01,
one-way
ANOVA).
administration
(20-150
μg/mL)
elicited
dose-dependent
suppression
PAR-2,
maximal
inhibition
100-150
μg/mL
0.001,
Tukey's
post
hoc
test).
Concomitant
reductions
transcription
0.01)
secretion
0.001)
observed,
corroborating
efficacy
OC.
Additionally,
ameliorated
LPS-induced
dysregulation,
restoring
intracellular
homeostasis
concentration-dependent
manner
0.01).
Crucially,
exhibited
selectivity
leaving
PAR-1
unaltered
>
0.05),
underscoring
precision
agent.
These
findings
position
selective
CRC,
disrupting
pro-tumorigenic
microenvironment
attenuation
secretion,
pathways.
furnishes
mechanistic
insights
into
OC's
potential
nutraceutical
intervention
inflammation-associated
CRC.
Given
variability
bioavailability
content
commercial
future
investigations
should
delineate
optimal
dosing
strategies
vivo
advance
translational
therapy.
Язык: Английский
Preparation of Carrier-Free Inhalable Dry Powder of Rivaroxaban Using Two-Step Milling for Lung-Targeted Delivery
Pharmaceutics,
Год журнала:
2025,
Номер
17(5), С. 634 - 634
Опубликована: Май 9, 2025
Background/Objectives:
This
study
aimed
to
develop
a
dry
powder
inhalation
(DPI)
formulation
of
rivaroxaban
(RVX)
using
combination
bead
milling
(BM)
and
jet
(JM)
enhance
lung-targeted
delivery
for
the
effective
treatment
pulmonary
embolism
while
minimizing
systemic
exposure.
Methods:
A
carrier-free
DPI
RVX
was
developed
sequential
BM
JM,
with
L-leucine
incorporated
at
various
concentrations
(1%,
5%,
10%)
as
force
control
agent.
The
formulations
were
characterized
particle
morphology,
size
distribution,
crystallinity,
thermal
properties.
in-vitro
aerodynamic
performance
evaluated
next-generation
impactor,
ex-vivo
studies
assessed
anticoagulant
activity.
Pharmacokinetic
tissue
distribution
carried
out
in
Sprague
Dawley
rats
following
intratracheal
administration,
effects
inhaled
compared
those
oral
administration.
Results:
optimized
BM-JM-5L
achieved
Dv50
2.58
±
0.01
µm
fine
fraction
72.10
2.46%,
indicating
suitability
delivery.
two-step
effectively
reduced
enhanced
dispersibility
without
altering
RVX’s
physicochemical
Ex-vivo
anticoagulation
tests
confirmed
maintained
or
improved
In-vivo
showed
that
administration
(5
mg/kg)
led
493-fold
increase
lung
drug
concentration
2.56-fold
higher
relative
bioavailability
vs.
dosing,
minimal
heart
accumulation,
confirming
targeted
Conclusions:
milled
formulations,
particularly
5%
leucine,
demonstrated
significant
potential
by
achieving
high
local
concentrations,
rapid
onset,
lower
doses.
These
findings
highlight
feasibility
treating
embolism.
Язык: Английский